As insurers minimal protection of behavioral ache therapy, biopharmaceutical suppliers sensed an opportunity. Pharmaceutical innovation propagated prolonged-release formulations, transdermal patches, nasal sprays, and oral dissolving strips. Clinical device makers drove a proliferation of novel sore